ReviewJournal of intensive care medicine2020
Therapeutic Plasma Exchange: A potential Management Strategy for Critically Ill COVID-19 Patients.
Review in Journal of intensive care medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 2 syntheses or guidelines pooled it, 62 citations in OpenAlex.
- What Is the Role of Therapeutic Plasma Exchange as an Adjunctive Treatment in Severe COVID-19: A Systematic Review.Viruses · 2021Pooled it
- The association between therapeutic plasma exchange and the risk of mortality among patients critically ill with COVID-19: a meta-analysis.F1000Research · 2021Pooled it
- Plasma exchange therapy for the post COVID-19 condition: a phase II, double-blind, placebo-controlled, randomized trial.Nature communications · 2025Trial
- Therapeutic plasma exchange in patients with life-threatening COVID-19: a randomised controlled clinical trial.International journal of antimicrobial agents · 2021Trial
- Efficacy of therapeutic plasma exchange in the treatment of penn class 3 and 4 cytokine release syndrome complicating COVID-19.Respiratory medicine · 2020Trial
- Early plasma exchange for severe fever with thrombocytopenia syndrome (SFTS)-associated encephalopathy and multi-organ dysfunction syndrome (MODS): a case report.BMC infectious diseases · 2026Article
- Therapeutic Plasma Exchange: Current and Emerging Applications to Mitigate Cellular Signaling in Disease.Biomolecules · 2025Review
- Enhancing Survival in Septic Shock: A Systematic Review and Meta-Analysis of the Efficacy of Plasma Exchange Therapy.Cureus · 2024Review
- Other Immunomodulatory Treatment for Cytokine Storm Syndromes.Advances in experimental medicine and biology · 2024Review
- Therapeutic plasma exchange in the treatment of COVID-19 induced cytokine storm: the first Moroccan experience.BMC infectious diseases · 2023Article
- Efficacy of plasmapheresis in neutropenic patients suffering from cytokine storm because of severe COVID-19 infection.Blood research · 2023Article
- The Impact of Therapeutic Plasma Exchange on Inflammatory Markers and Acute Phase Reactants in Patients with Severe SARS-CoV-2 Infection.Medicina (Kaunas, Lithuania) · 2023Review
- Assessing the Outcomes of Patients with Severe SARS-CoV-2 Infection after Therapeutic Plasma Exchange by Number of TPE Sessions.Journal of clinical medicine · 2023Article
- Effectiveness of COVID-19 Convalescent Plasma (CCP) During the Pandemic Era: A Literature Review.Journal of blood medicine · 2023Review
- Efficacy of Therapeutic Plasma Exchange in Severe Acute Respiratory Distress Syndrome in COVID-19 Patients from the Western Part of Romania.Medicina (Kaunas, Lithuania) · 2022Article
- The comparison of the mortality rates of plasmapheresis/hemoperfusion therapy with current treatment among Covid-19 patients.Heliyon · 2022Article
- Role of therapeutic plasma exchange in the management of COVID-19-induced cytokine storm syndrome.Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis · 2022Review
- Therapeutic plasma exchange in the intensive care unit and with the critically ill, a focus on clinical nursing considerations.Journal of clinical apheresis · 2022Article
- Effect of plasma exchange on COVID-19 associated excess of von Willebrand factor and inflammation in critically ill patients.Scientific reports · 2022Article
- Comparison of the Effects of Plasmapheresis, Hemoperfusion, and Convalescent Plasma Therapy on Inflammatory Factors in COVID-19 Patients.Medical journal of the Islamic Republic of Iran · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the 5 months since initial reports of COVID-19 came to light, the death toll due to SARS-CoV-2 has rapidly increased. The morbidity and mortality of the infection varies based upon patient age, comorbid conditions, viral load, and the availability of effective treatments. Findings from limited autopsies, clinical observations, and laboratory data suggest that high cytokine levels and a procoagulant state can precipitate acute respiratory distress syndrome and multi-organ dysfunction syndrome in critically ill patients. To complicate matters, comorbidities may affect the response to medical treatments currently in use, all of which are still in trial phase. Therapeutic plasma exchange (TPE) merits consideration in the treatment of critically ill COVID-19 patients and is an avenue for clinical trials to pursue. If efficacious, faster recovery of patients may lead to shorter intensive care unit stays and less time on mechanical ventilation. Herein, we briefly discuss some of the various approaches currently being investigated for the treatment of SARS-CoV-2 with a focus on potential benefits of TPE for selected critically ill patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.